Gapping up
In reaction to strong earnings/guidance: GV +20.8%, SYN +18.8%, CTRL+14.9%, YELP +13.7%, RATE +13.6%, HLF +12.8%, PACD +12.3%, SPPI +10.6%,UBNT +10.2%, MDR +8.6%, GSAT +8.2%, ACAD +7.2%, PTCT +6.8%, ATHX+6.8%, TRQ +6.7%, SWIR +6.6%, POST +6.5%, ATVI +6.3%, CLNE +5.5%, MTZ+5.4%, INAP +5%, NBIX +4.5%, HTGC +4.4%, BLDR +4.1%, AL +3.8%, ANET+3.8%, ATW +3.8%, TEAM +3.7%, MELI +3.4%, DV +3.2%, BATS +3.2%, VRNG+2.5%, WYNN +2.1%, UEIC +1.9%, CLVS +1.9%, WING +1.9%, WEB +1.8%, EXC+1.8%, MDVN +1.6%, EGY +1.6%, EVDY +1.5%, MAIN +1.4%, SAAS +1.1%, AHT+1%, RRMS +0.9%, EGN +0.9%
M&A news: RATE +13.6% (to acquire the business of NextAdvisor for ~$76.3 mln in cash and ~$3.00 mln in time-based vesting restricted stock units), APD+2.3% (confirms deal to sell the Performance Materials Division of its Materials Technologies segment to Evonik Industries for $3.8 bln)
Select metals/mining stocks trading higher: GOLD +1.7%, ABX +1.6%, GFI+0.7%, VALE +0.6%, GDX +0.5%
Other news: CRME +31.7% (Cardiome Pharma & Allergan (AGN) sign exclusive license agreement to commercialize Xydalba in France, the UK, Germany, Belgium, Nordic nations, and certain other European nations along with Canada and the middle east, additional terms undisclosed ), SPHS +21.1% (Sophiris Bio will present 'positive' data from its Phase 3 study of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia at the American Urological Association Annual Meeting on May 7)
Analyst comments: CTRV +3.1% (initiated with a Buy at Maxim Group; tgt $4),ARIA +2.5% (upgraded to Outperform from Market Perform at Cowen), MDVN+1.6% (upgraded to Buy from Neutral at Citigroup)
In reaction to strong earnings/guidance: GV +20.8%, SYN +18.8%, CTRL+14.9%, YELP +13.7%, RATE +13.6%, HLF +12.8%, PACD +12.3%, SPPI +10.6%,UBNT +10.2%, MDR +8.6%, GSAT +8.2%, ACAD +7.2%, PTCT +6.8%, ATHX+6.8%, TRQ +6.7%, SWIR +6.6%, POST +6.5%, ATVI +6.3%, CLNE +5.5%, MTZ+5.4%, INAP +5%, NBIX +4.5%, HTGC +4.4%, BLDR +4.1%, AL +3.8%, ANET+3.8%, ATW +3.8%, TEAM +3.7%, MELI +3.4%, DV +3.2%, BATS +3.2%, VRNG+2.5%, WYNN +2.1%, UEIC +1.9%, CLVS +1.9%, WING +1.9%, WEB +1.8%, EXC+1.8%, MDVN +1.6%, EGY +1.6%, EVDY +1.5%, MAIN +1.4%, SAAS +1.1%, AHT+1%, RRMS +0.9%, EGN +0.9%
M&A news: RATE +13.6% (to acquire the business of NextAdvisor for ~$76.3 mln in cash and ~$3.00 mln in time-based vesting restricted stock units), APD+2.3% (confirms deal to sell the Performance Materials Division of its Materials Technologies segment to Evonik Industries for $3.8 bln)
Select metals/mining stocks trading higher: GOLD +1.7%, ABX +1.6%, GFI+0.7%, VALE +0.6%, GDX +0.5%
Other news: CRME +31.7% (Cardiome Pharma & Allergan (AGN) sign exclusive license agreement to commercialize Xydalba in France, the UK, Germany, Belgium, Nordic nations, and certain other European nations along with Canada and the middle east, additional terms undisclosed ), SPHS +21.1% (Sophiris Bio will present 'positive' data from its Phase 3 study of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia at the American Urological Association Annual Meeting on May 7)
Analyst comments: CTRV +3.1% (initiated with a Buy at Maxim Group; tgt $4),ARIA +2.5% (upgraded to Outperform from Market Perform at Cowen), MDVN+1.6% (upgraded to Buy from Neutral at Citigroup)